KMT2A and leukemia: CBX8 interacts with the C-terminal domain of MLL-AF9 to mediate the transcriptional activation of the target gene of fusion protein MLL-AF9, thereby inducing leukemia.[8] The above findings demonstrate that CBX8 mainly plays a key role as an oncogene in some tumors.